Results for: Cystic Fibrosis

Dean Wicks’s reign of terror in EastEnders comes to an end as he faces the consequences of his actions. After returning to Walford last year, Dean’s attempts to reconcile with his daughter, Jade Green, take a sinister turn when he tampers with her medication and oxygen supply. However, Jade discovers the truth and makes plans to leave for Pakistan. Dean desperately tries to prevent her departure, but his efforts are futile. As Dean languishes in prison, Jade prepares to embark on a new chapter in her life, leaving behind the turmoil of Albert Square.

Arcturus Therapeutics is making strides in the treatment of cystic fibrosis, with their ARCT-032 treatment candidate recently receiving orphan drug designation. The treatment has the potential to be highly effective and is expected to generate substantial revenue upon commercialization, similar to Vertex Pharmaceuticals’ Trikafta. Arcturus is also developing a gene therapy for ornithine transcarbamylase deficiency, known as LUNAR-OTC, which is currently in Phase 2 clinical trials. Despite financial challenges, the company has a valuable portfolio of intellectual property and a strong pipeline of therapies. With positive clinical trial results for their cystic fibrosis and OTC therapies, Arcturus Therapeutics has the potential to become a dominant player in these markets.